Cargando…

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

BACKGROUND: The use of DTG-containing two-drug regimens is one of the most promising solutions to the need to ease the management of HIV treatment without harming its efficacy and safety. We report long- term results in patients switched, while virologically suppressed, to the combination of doluteg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maggiolo, Franco, Gulminetti, Roberto, Pagnucco, Layla, Digaetano, Margherita, Cervo, Adriana, Valenti, Daniela, Callegaro, Annapaola, Mussini, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558382/ https://www.ncbi.nlm.nih.gov/pubmed/36224538 http://dx.doi.org/10.1186/s12879-022-07769-6

Ejemplares similares

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study
por: Gagliardini, Roberta, et al.
Publicado: (2018)

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
por: Borghetti, Alberto, et al.
Publicado: (2019)

Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
por: Llibre, Josep M, et al.
Publicado: (2022)

Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark
por: Pedersen, Karen Brorup Heje, et al.
Publicado: (2023)

1603. Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2023)

Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients?
por: Tan, M, et al.
Publicado: (2019)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
por: Zamora, Francis J, et al.
Publicado: (2019)

Low-level residual viremia and risk of virological failure
por: Cologni, G, et al.
Publicado: (2010)

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
por: Borghetti, Alberto, et al.
Publicado: (2021)

Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV
por: Ergen, Pınar, et al.
Publicado: (2022)

Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea
por: Lee, Ki Hyun, et al.
Publicado: (2022)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
por: Wang, Ruolan, et al.
Publicado: (2023)

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
por: Radford, Matthew, et al.
Publicado: (2019)

Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis
por: Kabra, Madhusudan, et al.
Publicado: (2023)

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
por: Llibre, Josep M, et al.
Publicado: (2022)

Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
por: Giacomelli, Andrea, et al.
Publicado: (2020)

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
por: Suárez-García, Inés, et al.
Publicado: (2023)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
por: De Miguel Buckley, Rosa, et al.
Publicado: (2022)

1040. Real-World Implementation of Dolutegravir-Lamivudine to Achieve and Maintain HIV-1 Viral Suppression at an Academic Medical Center
por: Hiryak, Kayla, et al.
Publicado: (2020)

Qualitative study exploring the experiences and perceptions of dolutegravir/lamivudine dual antiretroviral therapy (the PEDAL study) in people living with HIV: protocol
por: Villa, Giovanni, et al.
Publicado: (2022)

Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine
por: Wohl, David, et al.
Publicado: (2018)

First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers
por: Francois, Kesner, et al.
Publicado: (2023)

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe
por: Kouamou, Vinie, et al.
Publicado: (2023)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
por: Cruciani, Mario, et al.
Publicado: (2015)

No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial
por: Li, Jonathan Z, et al.
Publicado: (2019)

Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine
por: Dumitrescu, Teodora Pene, et al.
Publicado: (2019)

Abacavir/dolutegravir/lamivudine: Delayed hepatotoxicity and drug-induced liver injury: case report
Publicado: (2021)

A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1
por: Shin, Sang-Kyu, et al.
Publicado: (2023)

Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1
Publicado: (2019)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uq9gs87pl819ta8mmrmtro5jq6